ADCY2

Across TCGA pan-cancer cohorts, ADCY2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADCY2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ADCY2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADCY2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

SCLC, UCEC, and ESCA are the cancer types where ADCY2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	III,IV	0.082	0.548	.003	24	view →
UCEC	DFS	Median	II,III,IV	0.838	0.300	.021	18	view →
ESCA	OS	Median	II,III,IV	0.109	0.931	<.001	15	view →
LUAD	DFS	Median	All	0.436	0.669	.015	4	view →
LUSC	OS	Median	All	0.694	0.389	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADCY2–SCLC (DFS)

Open the SCLC breakdown →